부인과 의약품 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Gynecology Drugs Market size is expected to reach USD 121.94 Billion in 2034 from USD 78.06 Billion (2025) growing at a CAGR of 5.08% during 2026-2034.

The Global Gynecology Drugs Market is growing steadily due to rising awareness about women's health and increasing prevalence of reproductive disorders. Conditions such as endometriosis, polycystic ovary syndrome (PCOS), and menopausal symptoms are driving demand for specialized gynecological medications. Expanding access to healthcare services is further supporting market expansion worldwide.

Major growth drivers include advancements in hormonal therapies and improved diagnostic techniques. Growing emphasis on family planning and fertility treatments is also contributing to increased drug utilization. Additionally, rising healthcare spending and government initiatives focused on maternal health are strengthening market growth.

Future prospects remain positive as research into targeted therapies and personalized treatments advances. Emerging markets are expected to offer substantial opportunities due to improving healthcare infrastructure and rising health awareness. Continued innovation in safer and more effective drug formulations will likely sustain long-term growth in the global gynecology drugs market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapeutics

• Hormonal Therapy
• Non-Hormonal Therapy

By Indication

• Gynecological Cancers
• Endometriosis
• Female Infertility
• Menopausal Disorder
• Gynecology Infections
• Polycystic Ovary Syndrome
• Contraception (Birth Control)
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Allergan plc, Amgen Inc, Bayer AG, Merck Co Inc, Pfizer Inc, Eli Lilly and Company, F HoffmannLa Roche Ltd, Ferring Holding SA, TherapeuticsMD Inc, AbbVie Inc, Pfizer Inc, AstraZeneca
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GYNECOLOGY DRUGS MARKET: BY THERAPEUTICS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapeutics
• 4.2. Hormonal Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Non-Hormonal Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GYNECOLOGY DRUGS MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Gynecological Cancers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Endometriosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Female Infertility Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Menopausal Disorder Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Gynecology Infections Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Polycystic Ovary Syndrome Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Contraception (Birth Control) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GYNECOLOGY DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GYNECOLOGY DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Therapeutics
  • 7.2.2 By Indication
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Therapeutics
  • 7.3.2 By Indication
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Therapeutics
  • 7.4.2 By Indication
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Therapeutics
  • 7.5.2 By Indication
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Therapeutics
  • 7.6.2 By Indication
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL GYNECOLOGY DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Allergan Plc
  • 9.2.2 Amgen Inc
  • 9.2.3 Bayer AG
  • 9.2.4 Merck & Co. Inc
  • 9.2.5 Pfizer Inc
  • 9.2.6 Eli Lilly And Company
  • 9.2.7 F. Hoffmann-La Roche Ltd
  • 9.2.8 Ferring Holding SA
  • 9.2.9 TherapeuticsMD Inc
  • 9.2.10 AbbVie Inc
  • 9.2.11 Pfizer Inc
  • 9.2.12 AstraZeneca